Table 1.
Baseline characteristics of patients with HCC and PVTT in the S-TACE or the A-TACE group.
| Characteristics | Sorafenib + TACE group (n = 32) | Apatinib + TACE group (n = 41) | P value |
|---|---|---|---|
| Age (years) | 52.7 ± 12.4 | 51.6 ± 9.6 | 0.678 |
| Gender | 0.723 | ||
| Male | 28 | 37 | |
| Female | 4 | 4 | |
| Child-Pugh class | 0.544 | ||
| A | 23 | 32 | |
| B | 9 | 9 | |
| Bilirubin (μmol/l)* | 19.00 (13.90, 30.30)# | 16.10 (12.35, 21.95)# | 0.397 |
| Albumin (g/l) | 34.98 ± 5.22 | 36.65 ± 5.07 | 0.173 |
| PT (s) | 13.77 ± 1.01 | 14.24 ± 1.78 | 0.180 |
| AFP level (ng/ml) | 0.644 | ||
| <400 | 15 | 17 | |
| ≥400 | 17 | 24 | |
| ECOG | 0.746 | ||
| 0 | 21 | 34 | |
| 1 | 11 | 8 | |
| HBV infection | 0.406 | ||
| Yes | 24 | 37 | |
| No | 8 | 4 | |
| Number of tumors | 0.156 | ||
| ≤3 | 24 | 36 | |
| >3 | 8 | 5 | |
| Tumor diameter (cm) | 4 | 14 | 0.054 |
| ≤5 | 28 | 27 | |
| >5 | 8.40 (6.43, 12.00)# | 7.20 (3.70, 11.15)# | |
| median* | 0.128 | ||
| PVTT type | 0.522 | ||
| 1 | 10 | 13 | |
| 2 | 21 | 24 | |
| 3 | 1 | 4 | |
| Ascites | 0.081 | ||
| Present | 18 | 31 | |
| Absent | 14 | 10 | |
| Extrahepatic spread | 0.845 | ||
| Present | 18 | 24 | |
| Absent | 14 | 17 | |
| TACE No. | 2.9 ± 1.6 | 3.7 ± 1.9 | 0.065 |
*Analyzed with the Mann-Whitney U-test.
#Represents median (interquartile range).
HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; S-TACE, sorafenib-transarterial chemoembolization; A-TACE, apatinib-transarterial chemoembolization; AFP, a-fetoprotein; ECOG, Eastern Cooperative Oncology Group.